Investor Presentation - First Six Months of 2021
4
Investor presentation First six months of 2021
Novo Nordisk®
Strategic Aspirations 2025 | Highlights first six months of 2021
Purpose and
sustainability
খ
Commercial
execution
Adding value to society:
Initiated Diabetes Compass with the WDF to improve
access to diabetes care in low- and middle-income
+
countries
Reaching 15 countries in Changing Diabetes in
Children by including Ghana
Progress towards zero environmental impact:
45% reduction in CO2 emissions vs the first six months
of 2019 and -15% reduction in supplier CO2 emissions
Evolve culture and ensure distinct core capabilities:
Launch of gender diversity target
Diabetes value market share increased by 0.5
percentage point to 29.6%¹
Obesity care sales increased by 34% at CER
to DKK 3.5 billion
Biopharm sales increased by 7% at CER
therapeutic focus
Innovation and
Financials
Diabetes care:
Blue indicates developments in Q2 2021
⚫ OzempicⓇ approved in China
•
•
.
Resubmission of semaglutide 2.0 mg in the US
Obesity care:
Decision to initiate phase 3a development with 50 mg oral
semaglutide in obesity
Approval of Wegovy TM, semaglutide 2.4 mg, in the US
Other serious chronic disease:
.
•
Phase 3a development programmes initiated for treatment
of NASH and Alzheimer's Disease
Stem cell R&D licence agreement with Heartseed and
acquisition of Prothena's ATTR amyloidosis programme
Sales growth of 12% and Operating profit growth of 9%:
Sales in International Operations grew by 13%
Sales in North America Operations grew by 11% and in the US,
56% of sales came from products launched since 2015
Gross margin positively impacted by productivity gains in
Product Supply
Free cash flow of DKK 32.7 billion and DKK 21.9 billion returned
to shareholders
The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth. Note: Unless otherwise specified growth rates are at constant exchange rates
1 MAT (Moving Annual Total) value market share
IO: International Operations; NAO: North America Operations; Sema: Semaglutide; NASH: Non-alcoholic steatohepatitis; FDA: Food and Drug Administration; EMA: European Medicines Agency; GHD: Growth Hormone Deficiency; HFPEF: Heart Failure with
preserved Ejection Fraction; WDF: World Diabetes Foundation; R&D: Research and Development; ATTR: Transthyretin AmyloidView entire presentation